LFB XENOTHERA agreement to manufacture XAV-19 candidate therapy for coronavirus, including COVID-19, infections
April 15, 2020

READ MORE >

FDA approves SEVENFACT®, a new recombinant coagulation Factor VIIa [coagulation factor VIIa
(recombinant)-jncw]
April 6, 2020

READ MORE >

Development of potential COVID-19 hyperimmune therapy
April 6, 2020

READ MORE >

LFB Future Strategy
February 19, 2019

READ MORE >

The LFB Group

A leader in the field of biopharmaceuticals in Europe

The LFB Group

Cultivating life-changing therapeutic proteins

The LFB Group

In the news